HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

53.150

-1.000-1.85%

Volume:318.00K

Turnover:17.11M

Market Cap:9.04B

PE:-25.31

High:55.500

Open:54.050

Low:52.250

Close:54.150

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:0.42

T/O Rate:0.19%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:4.47

PE(LYR):-25.31

PS:16.64

Loading ...

Overview Company News Filings

RIBOLIFE-B and MADRIGAL Achieve First Key Milestone in siRNA Collaboration

Suzhou Ribo Hits First Milestone in Madrigal Sirna Collaboration for MASH Drug Candidate

Suzhou Ribo Life Science to Buy 25.93% Stake in Azemidite

RIBOLIFE-B to Acquire Additional Stake in Subsidiary, Increasing Ownership to Approximately 88.17%

Suzhou Ribo Life Science Co Ltd - Deal for RMB70 Mln

THOMSON REUTERS

CMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target

Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity

Ribo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme

Bulletin Express

RIBOLIFE-B Plans Up to RMB 1 Billion H-Share Buyback and Purchase Program

RIBOLIFE Shareholders Approve All 2025 AGM Resolutions, Including H-Share Incentive Schemes and Articles Amendments

Bulletin Express

Suzhou Ribo shareholders back 2026 directors’ remuneration plan at AGM

Suzhou Ribo submits EMA Phase 2 trial application for RBD1119 in coronary artery disease

Ribo Announces Phase 2 Clinical Trial Submission to Ema, Further Advancing Sirna Therapeutics in Thromboembolic Disease

THOMSON REUTERS

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment

Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease

Bulletin Express

Soochow Securities Reiterates "Buy" Rating on RIBOLIFE-B (06938) Citing Advancements in Extrabepatic Delivery Technology

Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"

Ribo signs strategic collaboration with Insilico Medicine on AI-driven siRNA drugs

Insilico Medicine partners with Ribo Life Science on AI-driven oligonucleotide R&D

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/06938/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":53.15,"timestamp":1789373284009,"preClose":54.15,"halted":0,"volume":318000,"delay":0,"changeRate":-0.018467220683287166,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Closed","change":-1,"latestTime":"09-14 16:08:04","open":54.05,"high":55.5,"low":52.25,"amount":17108802,"amplitude":0.060018,"askPrice":53.2,"askSize":400,"bidPrice":53.15,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.15,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":0.422438,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":0.422438,"shares":170000000,"dividePrice":0,"high":55.5,"amplitude":0.060018,"preClose":54.15,"low":52.25,"week52Low":43.6,"pbRate":"4.47","psRate":"16.64","week52High":95.8,"institutionHeld":0,"latestPrice":53.15,"committee":-0.333333,"eps":-2.100221,"divideRate":0,"volume":318000,"delay":0,"ttmEps":-1.149,"open":54.05,"prevYearClose":57.97,"prevWeekClose":54.15,"prevMonthClose":60.25,"prevQuarterClose":46.9,"fiveDayClose":56.85,"twentyDayClose":51.2,"sixtyDayClose":49.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-09-11","current":-46.257615,"percent":0.121429,"low":-56.914635,"twenty":-39.680804,"median":-31.566896,"eighty":-26.683608,"high":-23.913403,"avg":-33.765632,"sd":8.127749,"marketCap":9235548376},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438},{"date":"2026-09-04","current":-56.914635,"twenty":-38.685171,"median":-30.913769,"eighty":-26.600296,"marketCap":11265151805},{"date":"2026-09-11","current":-46.597638,"twenty":-39.680804,"median":-31.566896,"eighty":-26.683608,"marketCap":9235548376}],"updateTime":1789376603319},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1186587424","title":"RIBOLIFE-B and MADRIGAL Achieve First Key Milestone in siRNA Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1186587424","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186587424?lang=en_us&edition=fundamental","pubTime":"2026-07-02 08:26","pubTimestamp":1782951980,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B has announced the achievement of the first candidate drug selection milestone in its siRNA collaboration project with Madrigal Pharmaceuticals.This partnership is focused on advancing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648522050","title":"Suzhou Ribo Hits First Milestone in Madrigal Sirna Collaboration for MASH Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2648522050","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648522050?lang=en_us&edition=fundamental","pubTime":"2026-07-02 08:01","pubTimestamp":1782950511,"startTime":"0","endTime":"0","summary":"Suzhou Ribo hits first milestone in Madrigal siRNA collaboration for MASH drug candidateSuzhou Ribo Life Science reached a first candidate drug nomination milestone in its siRNA partnership with Madri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL6QTG1Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK4585","06938","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648681905","title":"Suzhou Ribo Life Science to Buy 25.93% Stake in Azemidite","url":"https://stock-news.laohu8.com/highlight/detail?id=2648681905","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648681905?lang=en_us&edition=fundamental","pubTime":"2026-07-01 00:01","pubTimestamp":1782835278,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science To Buy 25.93% Stake In AzemiditeJune 30 (Reuters)-Suzhou Ribo Life Science Co Ltd6938.HK:TO BUY 25.93% EQUITY INTEREST IN AZEMIDITEDEAL FOR RMB70 MILLIONFurther company coverage:6938.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121370878","title":"RIBOLIFE-B to Acquire Additional Stake in Subsidiary, Increasing Ownership to Approximately 88.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121370878","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121370878?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:40","pubTimestamp":1782830443,"startTime":"0","endTime":"0","summary":"The company, RIBOLIFE-B (ASX: 06938), has announced the signing of a share transfer agreement with Haihe Cathay Fund. Under this agreement, the company will acquire a 25.93% equity interest in its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647521825","title":"Suzhou Ribo Life Science Co Ltd - Deal for RMB70 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2647521825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647521825?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:31","pubTimestamp":1782829878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320VG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177506769","title":"CMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1177506769","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177506769?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:18","pubTimestamp":1782112702,"startTime":"0","endTime":"0","summary":"CMSC International has released a research report initiating coverage on RIBOLIFE-B (06938) with an \"Add\" rating and a target price of HK$105. The firm is optimistic about the company's core asset,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","BK1564","EWH","06099","BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196165430","title":"Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=1196165430","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196165430?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:09","pubTimestamp":1780967340,"startTime":"0","endTime":"0","summary":"Major corporate announcements and significant share buybacks are drawing investor attention in the Hong Kong market today. SENASIC (ASX: 06675) has initiated its initial public offering process,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LI","LU3063872942.SGD","LU0823039010.USD","IE0003895053.USD","LU0762541174.USD","LU0633140727.USD","LU0143863198.USD","LU0502904849.HKD","LU1046422090.SGD","HK0000320264.USD","LU1733274473.HKD","01912","LU0328353924.USD","LU0348825331.USD","BK1214","IE00BZ08YR35.GBP","LU0456827905.SGD","LU1655091459.SGD","LU0700851271.USD","SG9999001846.SGD","LU0672654166.SGD","LU1983260115.SGD","LU0561508036.HKD","LU0132412106.USD","SG9999002828.SGD","LU1981816686.USD","LU2362540622.SGD","LU0918141887.USD","LU0384037296.USD","LU0205439572.USD","LU0261947096.USD","LU0873338254.USD","LU1515016050.SGD","SG9999000327.SGD","81299","LU2251237488.HKD","LU1282649810.SGD","LU0345769631.USD","LU0203345920.USD","LU0348735423.USD","LU0417516571.SGD","LU0856984785.SGD","LU0898667661.SGD","LU1504937902.USD","LU0197773160.USD","02359","LU1105468828.SGD","BK1618","LU1868837565.USD","605499","LU1439103000.SGD","LU1868837722.USD","LU2133065610.SGD","LU0307460666.USD","LU0127658192.USD","LU0251144936.SGD","LU2462611646.USD","LU1251922891.USD","LU1400636657.SGD","LU0762540952.USD","LU1769817096.USD","SG9999007991.SGD","LU1770034418.SGD","LU1400636491.USD","SG9999001689.USD","HK0000352382.USD","HK0000306701.USD","SG9999004220.SGD","LU0140636845.USD","LU0314109678.HKD","LU0543330566.HKD","LU0359202008.SGD","LU0862451837.USD","SG9999000459.SGD","LU0106252389.USD","LU0572939691.SGD","LU0051755006.USD","LU0197773673.USD","LU0708995583.HKD","HK0000288743.USD","LU0072462343.USD","LU0181495838.USD","LU2328871848.SGD","LU2177674079.SGD","LU1804176565.USD","LU2237443549.SGD","LU0488056044.USD","LU0049853897.USD","LU1064130708.USD","LU2125910849.SGD","SG9999004303.SGD","LU0640798160.USD","03898","BK1515","GB00BDT5M118.USD","LU0348816934.USD","LU0594300179.USD","LU0918141705.HKD","LU0455707207.USD","IE0003795394.USD","SG9999001051.SGD","LU1048596156.SGD","IE00BQXX3D17.EUR","LU0675040207.SGD","LU1439102457.SGD","IE00BFXG0V08.USD","LU0269904917.USD","LU0266013472.USD","603259","LU2148510915.USD","LU0511384066.AUD","LU1226288253.USD","01093","LU0244354667.USD","BK1539","BK1183","LU2498475776.HKD","LU0823040885.USD","01681","LU2237443382.USD","BK1151","LU0048388663.USD","LU2008162690.USD","LU0164880469.USD","LU1226287792.SGD","BK1588","LU0414403682.SGD","LU1969619763.USD","LU2247934214.USD","LU1328615791.USD","LU0196878994.USD","IE0004091025.USD","LU0128522744.USD","LU0868486357.SGD","LU0456846285.SGD","LU2257852520.SGD","LU0971096721.USD","BK1608","BK1565","LU2362541513.USD","LU0516422952.EUR","LU1226287529.USD","LU1282648689.USD","SG9999002562.SGD","LU0348827113.USD","SG9999001226.SGD","BK1521","LU0289961442.SGD","LU0821914370.USD","LU0588546209.SGD","LU0203347892.USD","IE0001KFT4U8.USD","LU1328277881.USD","LU1366334578.USD","LU0254981946.USD","HK0001040143.USD","LU0828238088.HKD","IE00B0JY6N72.USD","LU1629966141.USD","LU1831875114.USD","LU0052750758.USD","LU0683595622.HKD","LU1688375341.USD","LU0509642566.USD","LU0831103253.SGD","LU1044874839.SGD","LU0882747503.HKD","LU0326948709.USD","LU2097828805.USD","000333","IE00BZ08YS42.EUR","09699","SGXZ31699556.SGD","LU0702159699.USD","LU1568876251.USD","SG9999014880.SGD","HK0000151867.HKD","06938","LU0327786744.USD","LU1196710351.USD","LU0043850808.USD","LU0359201885.HKD","00300","LU1807302812.USD","BK1610","LU2242644610.SGD","IE00B97KM107.HKD","LU0762542818.HKD","LU0164872284.USD","LU0117841782.USD","LU0348784397.USD","LU1770036033.HKD","BK1590","LU0211331839.USD","HK0000288784.HKD","LU0320764755.SGD","01334","BK1502","IE0032834883.USD","BK1518","LU0786609619.USD","BK1606","LU0029874905.USD","LU0211977185.USD","SG9999001903.USD","LU0251143458.SGD","SG9999015945.SGD","LU1645745479.HKD","LU0011963245.USD","LU0315179316.USD","LU0608807946.USD","LU1868838027.USD","LU0345775950.USD","LU0880133367.SGD","BK1516","LU2294711473.HKD","BK1200","BK1171","HK0000914686.HKD","IE00B031HW06.USD","LU2399975544.HKD","LU0516422440.USD","SG9999014039.USD","LU0823426480.USD","SGXZ81514606.USD","688331","IE00B0169L03.USD","LU0348805143.USD","SG9999017495.SGD","LU0541501648.USD","SG9999001069.SGD","LU0231483743.USD","LU0049112450.USD","LU1282651121.HKD","LU2153592121.USD","LU0039217434.USD","LU0588545490.SGD","LU1051769294.HKD","LU1119993845.HKD","BK1574","LU1102505929.USD","IE00B8HQ1Z84.USD","WXXWY","LU0228367735.SGD","LU1810669033.SGD","SG9999014674.SGD","LU1718418525.SGD","LU0210527791.USD","LU0878005551.USD","LU0158827948.USD","LU2111349929.HKD","SG9999018857.SGD","LU1064131003.USD","LU0293314216.USD","LU0096374516.USD","LU1048588211.SGD","LU1366334651.USD","LU0261950983.USD","BK1614","LU0320764243.SGD","IE0034224299.USD","LU0054237671.USD","SG9999015952.SGD","LU0738912210.USD","IE00B3M56506.USD","LU0106959298.USD","SG9999003461.SGD","LU0261950470.USD","IE00BF5LJ272.USD","LU0737861699.HKD","SG9999014914.USD","LU1725190679.HKD","IE00B543WZ88.USD","LU0791590937.USD","LU2106854487.HKD","LU0084288322.USD","SG9999000418.SGD","BK1155","LU0149721374.USD","LU0557290698.USD","HK0000352291.HKD","IE0004086264.USD","09980","LU0456842615.SGD","LU0029875118.USD","LU0169518387.USD","IE00B5TLWC47.USD","BK1589","LU2348774022.SGD","LU2097828474.EUR","LU1808992512.USD","LU0608807433.USD","LU1282651048.USD","LU1171460220.USD","SG9999006597.SGD","LU0541502299.USD","02269","LU0192582467.USD","LU0955648018.USD","LU0955669360.SGD","BK1594","LU0865486749.SGD","LU0067412154.USD","LU0572944931.SGD","LU0345780950.USD","SG9999018865.SGD","LU0164865239.USD","SG9999015986.USD","IE00B5MMRT66.SGD","IE00BYQQ9H92.USD","IE00B8L5B284.USD","TCHmain","LU1316542783.SGD","LU0823397103.USD","BK1526","LU0348767384.USD","BK1167","SG9999014906.USD","BK1609","LU0149534421.HKD","LU0594300419.USD","LU2097828714.EUR","LU2476274720.SGD","TCEHY","LU1400636574.HKD","LU0117844026.USD","LU1152091754.HKD","LU1883866441.USD","688187","LU0862451753.SGD","LU1785774172.SGD","LU1993786604.SGD","LU1961090484.USD","LU0431992006.USD","LU1166156734.SGD","LU0348766576.USD","LU0259732245.USD","IE0032431581.USD","LU2237443622.USD","LU1956131251.USD","06622","IE0009570106.USD","LU1008478684.HKD","LU1769817179.HKD","SG9999014013.SGD","LU2237443465.HKD","02015","IE00BGV7N243.SGD","LU0630314457.HKD","LU2449936058.SGD","LU0348723411.USD","LU2152927971.USD","LU0047713382.USD","HK0000914660.USD","SG9999001093.SGD","LU0315178854.USD","LU1224444064.USD","LU0048580855.USD","LU0329678170.USD","LU0543330483.HKD","LU0396098781.USD","LU0572940350.SGD","LU0828237510.HKD","LU2348773727.SGD","LU0611395673.USD","LU2362541273.HKD","AAGIY","LU1691799644.USD","LU1303224171.USD","LU0417516738.SGD","HTCD.SI","LU0463099449.HKD","LU0345781412.USD","LU1720050803.USD","BK1141","SGXZ99366536.SGD","HK0000320223.HKD","LU2089284900.SGD","LU2153591404.USD","LU0831093199.SGD","SG9999015978.USD","IE00BQXX3C00.GBP","LU0588545904.SGD","LU0229945570.USD","LU2051468812.USD","LU0210533765.USD","LU1226288097.SGD","LU0061477393.USD","002747","LU1188198961.HKD","LU0828237940.HKD","IE0003851619.USD","LU1242518931.SGD","LU0289739343.SGD","LU0054450605.USD","IE0008368411.USD","LU0819123356.HKD","LU2045819591.USD","LU0329678337.USD","LU1196710864.SGD","LU0214875030.USD","LU0320764599.SGD","IE0031814852.USD","BK1175","LU0823038988.USD","LU0107464264.USD","LU0069063385.USD","LU0359201612.USD","LU1481107354.HKD","IE00BKZH1Z71.USD","LU0128522157.USD","LU0972618739.USD","LU0370786039.SGD","01333","BK1583","LU0499858602.USD","LU0823426308.USD","LU1115378108.SGD","LU2023251221.USD","LU2279701549.SGD","IE00BZ08YT58.USD","LU0985320562.USD","LU1051768304.USD","SG9999014021.USD","LU0057025933.USD","LU1235295612.USD","LU0235996351.USD","SG9999014005.SGD","LU0080751232.USD","LU0531971595.HKD","LU0163747925.USD","LU0264606111.USD","LU1821325948.USD","IE00BPRC5H50.USD","LU2293587155.HKD","LU1733274390.USD","LU0823413660.USD","LU1323998911.USD","LU1044876610.USD","LU1960683339.HKD","LU0648948544.HKD","00700","09995","LU0106259558.USD","LU1242518857.USD","LU0165289439.USD","BK1500","LU0633140560.USD","LU0784639295.USD","LU1152091168.USD","LU0979878070.USD","LU1048484197.HKD","IE00B067MR52.USD","LU0531970944.HKD","LU1044875133.USD","LU0348814723.USD","LU0588545730.USD","LU1734074674.USD","LU0072913022.USD","LU0819121731.USD","BK1531","LU0210526637.USD","LU2028103732.USD","LU0326950275.SGD","LU1196710195.USD","LU2097828631.EUR","LU1282649141.HKD","BK1161","LU0651947912.USD","LU1719994722.HKD","LU1130305938.SGD","LU1974910355.USD","BK1592","LU1951186391.HKD","BK1184","LU0158827781.USD","BK1586","LU0348783233.USD","IE00B0169N27.USD","02715","LU0441854154.USD","LU1880383366.USD","LU0877626530.USD","LU0955623706.USD","BK1517","BK1575","LU2226246903.HKD","IE00B031J352.USD","LU1880383440.USD","LU2089283258.USD","SGXZ90724238.SGD","LU0886674414.USD","LU0605514214.HKD","LU0823413587.USD","LU1211504680.USD","BK1615","LU1794554557.SGD","LU1670756490.USD","LU0630378429.USD","01652","LU1226288170.HKD","LU0175139822.USD","IE00B3T34201.USD","00354","BK1116","LU1814569148.SGD","BK1119","LU0188438112.USD","BK1576","LU0173614495.USD","LU2778985437.USD","LU0228659784.USD","LU2271345857.HKD","LU1202635105.USD","LU2237443978.SGD","LU2125910500.SGD","LU2279858448.HKD","LU1642822792.SGD","LU0577902298.EUR","SGXZ51526630.SGD","LU0417516902.SGD","LU0797268264.HKD","LU0348783662.USD","06675","LU0577902454.USD","LU0143863784.USD","LU0630378692.HKD","LU1282649067.USD","LU2097828557.USD","LU1813983027.USD","LU2237443895.HKD","01378","01024","LU0589944569.HKD","LU2317271919.USD","01299","SG9999013353.USD","HK0001040168.HKD","LU0499858438.USD","LU1224709979.USD","LU0607220059.USD","IE0008368742.USD","LU0634319403.HKD","LU0048597586.USD","SG9999014898.SGD","LU1023057109.AUD","HK0000306685.HKD","LU1363072403.SGD","BK1095","SG9999002463.SGD","LU2023250504.SGD","IE00B031HY20.USD","LU0540923850.HKD","LU1102505762.USD","LU0469268626.HKD","LU2039709279.SGD","LU0577902611.USD","LU0642271901.SGD","LU0890818403.SGD","LU0791591158.USD","SG9999006514.SGD","LU0348788117.USD","LU1568876335.HKD","LU0449515922.USD","BK1191","LU0878004406.USD","LU0593848301.USD","LU1481012133.USD","LU0650527681.SGD","LU0345776255.USD","LU0472753341.HKD","LU0651946864.USD","LU0577902538.SGD","LU2251237306.USD","KSTmain","IE00BQXX3F31.USD","LU0871576103.HKD","BK1591","LU0449509016.USD","LU1712237335.SGD","LU0823397285.USD","SGXZ23171101.USD","LU0516422366.SGD","IE0008369823.USD","81024","HK0000165453.HKD","IE00B29SXG58.USD","LU0289960550.SGD","LU2476274308.USD","LU0287142896.SGD","LU0577902371.SGD","LU0516423091.SGD","BK1587","LU0516423174.USD","LU0501845795.SGD","LU1226287875.USD","LU0048575426.USD","LU1623119135.USD","LU0737861772.HKD","LU0345769128.USD","LU2265009873.SGD","LU1917777945.USD","LU1675838814.USD","LU0708995153.HKD","LU0823041008.USD","LU0070217475.USD","LU2087589342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152243913","title":"Ribo Life Science announces up to RMB200.00 million H-share purchase and repurchase programme","url":"https://stock-news.laohu8.com/highlight/detail?id=1152243913","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152243913?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:44","pubTimestamp":1780908262,"startTime":"0","endTime":"0","summary":"On 8 June 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life Science”) disclosed a voluntary plan to deploy a combined ceiling of RMB200.00 million in the Hong Kong market over the next 12 months....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150245696","title":"RIBOLIFE-B Plans Up to RMB 1 Billion H-Share Buyback and Purchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1150245696","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150245696?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:40","pubTimestamp":1780908039,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B has announced its intention to utilize up to RMB 1 billion of internal funds for a share purchase program.The company plans to appoint a professional trustee to acquire its H-shares over a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165897219","title":"RIBOLIFE Shareholders Approve All 2025 AGM Resolutions, Including H-Share Incentive Schemes and Articles Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=1165897219","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165897219?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:43","pubTimestamp":1780663380,"startTime":"0","endTime":"0","summary":"On 5 June 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE) held its 2025 Annual General Meeting in Beijing. Shareholders representing 76.81 million H shares, or 45.04 % of the issued share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148556","title":"Suzhou Ribo shareholders back 2026 directors’ remuneration plan at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148556?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:33","pubTimestamp":1780662831,"startTime":"0","endTime":"0","summary":"Shareholders backed a 2026 directors’ remuneration plan, authorizing the board to set directors’ pay; 74,955,374 votes for, 1,858,075 abstained.Meeting also passed H Share Option Scheme, H Share Incentive Scheme, related limits; each drew 64,874,926 for, 7,640,899 against, 4,297,624 abstained.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL7grPcv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638065664","title":"Suzhou Ribo submits EMA Phase 2 trial application for RBD1119 in coronary artery disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638065664","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638065664?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:52","pubTimestamp":1779936752,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science submitted a Phase 2 clinical trial application to the EMA for RBD1119, an siRNA candidate for coronary artery disease.The filing extends Ribo’s anticoagulation pipeline in thromboembolic disease, targeting improved efficacy with lower bleeding risk versus current therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire  on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7wdZ80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638616656","title":"Ribo Announces Phase 2 Clinical Trial Submission to Ema, Further Advancing Sirna Therapeutics in Thromboembolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638616656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638616656?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:51","pubTimestamp":1779936705,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA7QDPT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK1161","BK7129","06938","EMA.AU","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123219623","title":"RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1123219623","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123219623?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:50","pubTimestamp":1779925820,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181474011","title":"Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1181474011","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181474011?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:42","pubTimestamp":1779921770,"startTime":"0","endTime":"0","summary":"On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182573492","title":"Soochow Securities Reiterates \"Buy\" Rating on RIBOLIFE-B (06938) Citing Advancements in Extrabepatic Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1182573492","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182573492?lang=en_us&edition=fundamental","pubTime":"2026-05-20 14:54","pubTimestamp":1779260076,"startTime":"0","endTime":"0","summary":"Soochow Securities Company Limited. has released a research report maintaining a \"Buy\" rating on RIBOLIFE-B (06938). The report notes that the company's current revenue primarily stems from milestone...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK0276","BK0012","BK0009","601555","BK1161","BK0028","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100532115","title":"Registration Open for \"Zhihui Financial 2026 Summer Roadshow Conference\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1100532115","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100532115?lang=en_us&edition=fundamental","pubTime":"2026-05-18 10:47","pubTimestamp":1779072449,"startTime":"0","endTime":"0","summary":"In the first half of 2026, the Hong Kong capital market is experiencing a long-awaited period of heightened activity. Since the second quarter, the Hong Kong market has been on a sustained recovery...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06682","LU0588546209.SGD","BK1191","06636","BK1147","LU0469268626.HKD","01396","BK1100","BK1149","LU1166156734.SGD","01333","02526","HK0001040143.USD","BK1592","LU1023057109.AUD","BK1230","01907","LU0345780950.USD","BK1162","BK1129","03858","BK1258","BK1190","BK1617","02706","LU0314109678.HKD","LU1303224171.USD","03317","BK1169","BK1240","02142","02726","02659","BK1163","BK1161","06051","BK1500","SG9999014674.SGD","LU0359201612.USD","BK4588","VXUS","03881","LU0359202008.SGD","SG9999001093.SGD","BK1109","BK1541","02565","06938","00363","BK1207","02729","00826","02411","02675","BK1198","06651","LU0307460666.USD","BK1578","08299","BK1506","BK1594","BK1110","09696","LU2039709279.SGD","02650","BK1141","LU0737861699.HKD","HK0001040168.HKD","LU0572939691.SGD","06090","BK1205","BK1183","LU1813983027.USD","01300","BK1574","LU0173614495.USD","BK1225","BK1229","01378","02655","BK1171","LU1224709979.USD","BK1155","00400","02228","00290","02889","LU1328277881.USD","02623","02652","BK1249","00650","00305","BK1117","02575","BK1116","BK1144","BK1583","BK1613","01384","LU0359201885.HKD","01021","LU0630314457.HKD","LU0287142896.SGD","02670","BK1142","LU0572940350.SGD","BK1175","BK1238","LU1251922891.USD","LU1770034418.SGD","LU0345781412.USD","LU1719994722.HKD","LU0264606111.USD","BK1132","BK4585","02685","LU0702159699.USD","BK1539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635737710","title":"Ribo signs strategic collaboration with Insilico Medicine on AI-driven siRNA drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635737710","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635737710?lang=en_us&edition=fundamental","pubTime":"2026-05-14 03:06","pubTimestamp":1778699191,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science entered strategic collaboration agreement with Insilico Medicine on May 13, 2026 to speed development of AI-enabled siRNA drugs.Partnership targets joint work on therapeutic target identification, siRNA drug design and optimization, AI-assisted development, clinical translation.Deal builds on earlier collaboration in autonomous high-throughput intelligent screening, with Insilico platform Pharma.AI slated to support oligonucleotide development programs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbBnc6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211380","title":"Insilico Medicine partners with Ribo Life Science on AI-driven oligonucleotide R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211380","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211380?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:32","pubTimestamp":1778589161,"startTime":"0","endTime":"0","summary":"Insilico Medicine Cayman Topco entered strategic collaboration agreement with Suzhou Ribo Life Science to expand joint work on RNA interference and oligonucleotide therapeutics development.Deal pairs Insilico Pharma.AI drug discovery platform with Ribo oligonucleotide development capabilities, targeting faster end-to-end R&D execution.Cooperation builds on existing experimental services work tied to Insilico LifeStar 2 automated laboratory, where Ribo is first high-throughput services partner.Ribo cited prior partnerships valued at more than USD 6 billion, positioning collaboration as part of its broader business development strategy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7dXJ27:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696","BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":92,"code":"91000000","status":"200"}]}}